Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

Abstract: The present invention provides compounds of formula I 1

Abstract: The present invention provides compounds of formula I 1

Abstract: The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.

Abstract: The present invention provides compounds of formula I 1

Abstract: Compounds of the formula ##STR1## which inhibit leukocyte adhesion mediated by interaction of the .alpha..sub.4 .beta..sub.1 integrin (VLA-4) with its counterreceptor VCAM-1, and their use for the treatment of inflammatory and autoimmune diseases.

Abstract: This invention relates to novel PDE-IV inhibitors having the formula: ##STR1## where: R.sup.1 =H, C.sub.1 -C.sub.6 alkyl;R.sup.2 =C.sub.3 -C.sub.7 alkyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.4 -C.sub.8 cycloalkylidene when Y is CH; ##STR2## R.sup.4 =H, OR.sup.5, NHR.sup.5, NHOH, NHNH.sub.2 or ##STR3## R.sup.5 =H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl or ##STR4## W=N or CH; X=CH.sub.2, O, S, or NH;Y=CH.sub.2, CH, O, S, or NH;Q=a bond or CH.dbd.CH;n=0, 1, 2, 3 or 4;M=O, NOH or H.sub.2 ;Z=H or halogen;or a pharmaceutically acceptable salt thereof, as antiasthmatic agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.3-7 alkyl or C.sub.3-7 cycloalkyl;R.sup.3 is hydrogen, lower alkyl, carboxyloweralkyl, lower alkoxycarbonyl, lower alkoxycarbonyl loweralkyl, aryl or aralkyl;R.sup.4 is hydrogen, C.sub.1-8 alkyl, ##STR2## B is a bond, NH or O; Y is O or S;A is a bond or --C.dbd.C--;n is 0-5R.sup.5 may be hydrogen when B is NH, orR.sup.5 is lower alkyl, C.sub.3-8 cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, aralkenyl, aralkenylalkyl, ##STR3## --(CH.sub.2).sub.n NR.sup.1 R.sup.1 or --(CH.sub.2).sub.n het, where het is a 5- or 6-membered, saturated or unsaturated, nitrogen- or sulfur- or oxygen-containing monoheterocycle, optionally substituted with lower alkyl or oxo;R.sup.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.3-7 alkyl or C.sub.3-7 cycloalkyl;R.sup.3 is hydrogen, lower alkyl, carboxyloweralkyl, lower alkoxycarbonyl, lower alkoxycarbonyl loweralkyl, aryl or aralkyl;R.sup.4 is hydrogen, C.sub.1-8 alkyl, ##STR2## B is a bond, NH or O; Y is O or S;A is a bond or --C.dbd.C--;n is 0-5;R.sup.5 is hydrogen when B is NH, orR.sup.5 is lower alkyl, C.sub.3-8 cycloalkyl; aryl, substituted aryl, aralkyl, substituted aralkyl, aralkenyl, aralkenylalkyl or ##STR3## R.sup.6 is hydrogen or halo; the dotted line represents an optional double bond; andthe pharmacologically acceptable salts thereof, which by virtue of their ability to selectively inhibit PDE IV, are bronchodilatory and anti-inflammatory and so are useful in the treatment of acute and chronic bronchial asthma and associated pathologies.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R is ##STR2## R.sup.1 is hydrogen, lower alkyl or ##STR3## a is 1-3; b is 1-3;c is 0-2;X, Y and Z are each, independently, a bond, O, S. or NH, with the proviso that if one of X or Y is O, S or NH, the other must be a bond;R.sup.2 is amino, loweralkylamino, arylamino, loweralkoxy or aryloxy;R.sup.3 is hydrogen, halo, hydroxy, lower alkoxy, aryloxy, loweralkanoyloxy, amino, lower alkylamino, arylamino or loweralkanoylamino;R.sup.4 and R.sup.5 are each, independently hydrogen or lower alkyl;m is 0-4;n is 1-4; ando is 1-4;and, which by virtue of their ability to selectively inhibit an isoenzyme of 3':5'-cyclic AMP phosphodiesterase located in pulmonary smooth muscle tissue and inflammatory cells, are bronchodilatory and antinflammatory and so are useful in the treatment of acute and chronic bronchial asthma and associated pathologies.

Abstract: This invention relates to novel [(substituted naphthalenyl)alkyl]-3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical compositions thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.

Abstract: This invention relates to novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides, processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.